Sangamo Therapeutics (SGMOQ) Free Cash Flow (2010 - 2025)

Sangamo Therapeutics has reported Free Cash Flow for 16 years, with the latest figure at -$24.4 million in Q4 2025.

• On a quarterly basis, Free Cash Flow fell 656.18% year-over-year to -$24.4 million in Q4 2025; TTM through Dec 2025 was -$97.3 million, a 44.36% decrease from a year earlier, with the FY2025 full-year figure at -$97.3 million, down 44.36% from the prior year.
• Free Cash Flow was -$24.4 million for Q4 2025 at Sangamo Therapeutics, up from -$28.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $11.8 million in Q3 2024, with the low at -$76.5 million in Q1 2021.
• Average Free Cash Flow over 5 years is -$45.6 million, with a median of -$54.4 million recorded in 2021.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow jumped 123.59% in 2024, then tumbled 656.18% in 2025.
• Over 5 years, Free Cash Flow stood at -$55.6 million in 2021, then slipped by 16.11% to -$64.5 million in 2022, then climbed by 17.53% to -$53.2 million in 2023, then jumped by 93.93% to -$3.2 million in 2024, then sank by 656.18% to -$24.4 million in 2025.
• The last three Free Cash Flow figures came in at -$24.4 million (Q4 2025), -$28.5 million (Q3 2025), and -$18.0 million (Q2 2025), per Business Quant data.